Design of modified U1i molecules against HIV-1 RNA

Antiviral Research

Volumn 94, Issue 3, 2012, Pages 208-216

  Knoepfel, Stefanie A ^a   Abad, Amaya ^b   Abad, Xabi ^b   Fortes, Puri ^b   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Gene therapy; HIV 1; Inhibition; Modified U1 snRNAs; RNA degradation; U1 interference

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; U1 INTERFERENCE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRUSES, HUMAN; ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CELL LINE; HIV-1; HUMANS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 84860298138     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.03.010     Document Type: Article

References (46)

1. Abad X., Vera M., Jung S.P., Oswald E., Romero I., Amin V., Fortes P., Gunderson S.I. Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucleic Acids Res. 2008, 36:2338-2352.
2. Abad X., Razquin N., Abad A., Fortes P. Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression. Nucleic Acids Res. 2010, 38:e136.
3. Anderson J., Li M.J., Palmer B., Remling L., Li S., Yam P., Yee J.K., Rossi J., Zaia J., Akkina R. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol. Ther. 2007, 14:1182-1188.
4. Banerjea A., Li M.J., Bauer G., Remling L., Lee N.S., Rossi J., Akkina R. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol. Ther. 2003, 8:62-71.
5. Barré-Sinoussi F., Chermann J.C., Rey P., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
6. Beckley S.A., Liu P., Stover M.L., Gunderson S.I., Lichtler A.C., Rowe D.W. Reduction of target gene expression by a modified U1 snRNA. Mol. Cell Biol. 2001, 21:2815-2825.
7. Cochrane A.W., McNally M.T., Mouland A.J. The retrovirus RNA trafficking granule: from birth to maturity. Retrovirology 2006, 3:18.
8. Das A.T., Harwig A., Berkhout B. The HIV-1 Tat protein has a versatile role in activating viral transcription. J. Virol. 2011, 85:9506-9516.
9. DiGiusto D.L., Krishnan A., Li L., Li H., Li S., Rao A., Mi S., Yam P., Stinson S., Kalos M., Alvarnas J., Lacey S.F., Yee J.K., Li M., Couture L., Hsu D., Forman S.J., Rossi J.J., Zaia J.A. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010, 2:36ra43.
10. Fortes P., Cuevas Y., Guan F., Liu P., Pentlicky S., Jung S.P., Martinez-Chantar M.L., Prieto J., Rowe D., Gunderson S.I. Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc. Natl Acad. Sci. USA 2003, 100:8264-8269.
11. Gunderson S.I., Polycarpou-Schwarz M., Mattaj I.W. U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol. Cell 1998, 1:255-264.
12. Jankowska A., Gunderson S.I., Andrusiewicz M., Burczynska B., Szczerba A., Jarmolowski A., Nowak-Markwitz E., Warchol J.B. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol. Cancer 2008, 7:26.
13. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., de Baar M., Verhoef K., Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of HIV-1 subtypes A through G. J. Virol. 2000, 74:3740-3751.
14. Kato K., Hitomi Y., Imamura K., Esumi H. Hyperstable U1snRNA complementary to the K-ras transcripts induces cell death in pancreatic cancer cells. Br. J. Cancer 2002, 87:898-904.
15. Koornneef A., van Logtenstein R., Timmermans E., Pisas L., Blits B., Abad X., Fortes P., Petry H., Konstantinova P., Ritsema T. AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i. Gene Ther. 2011, 18:929-935.
16. Kwek K.Y., Murphy S., Furger A., Thomas B., O'Gorman W., Kimura H., Proudfoot N.J., Akoulitchev A. U1 snRNA associates with TFIIH and regulates transcriptional initiation. Nat. Struct. Biol. 2002, 9:800-805.
17. Levine B.L., Humeau L.M., Boyer J., MacGregor R.R., Rebello T., Lu X., Binder G.K., Slepushkin V., Lemiale F., Mascola J.R., Bushman F.D., Dropulic B., June C.H. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl Acad. Sci. USA 2006, 103:17372-17377.
18. Li M.J., Kim J., Li S., Zaia J., Yee J.K., Anderson J., Akkina R., Rossi J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12:900-909.
19. Liu P., Kronenberg M., Jiang X., Rowe D. Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript. Nucleic Acids Res. 2004, 32:1512-1517.
20. Liu Y.P., von Eije K.J., Schopman N.C., Westerink J.T., Ter Brake O., Haasnoot J., Berkhout B. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol. Ther. 2009, 17:1712-1723.
21. Lu X., Humeau L., Slepushkin V., Binder G., Yu Q., Slepushkina T., Chen Z., Merling R., Davis B., Chang Y.N., Dropulic B. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J. Gene Med. 2004, 6:963-973.
22. Lu X., Yu Q., Binder G.K., Chen Z., Slepushkina T., Rossi J., Dropulic B. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 2004, 78:7079-7088.
23. Mandal D., Feng Z., Stoltzfus C.M. Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs. J. Virol. 2010, 84:12790-12800.
24. Marzio G., Verhoef K., Vink M., Berkhout B. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl Acad. Sci. USA 2001, 98:6342-6347.
25. Marzio G., Vink M., Verhoef K., de Ronde A., Berkhout B. Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription. J. Virol. 2002, 76:3084-3088.
26. Mitsuyasu R.T., Merigan T.C., Carr A., Zack J.A., Winters M.A., Workman C., Bloch M., Lalezari J., Becker S., Thornton L., Akil B., Khanlou H., Finlayson R., McFarlane R., Smith D.E., Garsia R., Ma D., Law M., Murray J.M., von Kalle C., Ely J.A., Patino S.M., Knop A.E., Wong P., Todd A.V., Haughton M., Fuery C., Macpherson J.L., Symonds G.P., Evans L.A., Pond S.M., Cooper D.A. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34(+) cells. Nat. Med. 2009, 15:285-292.
27. Morris K.V., Chan S.W., Jacobsen S.E., Looney D.J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004, 305:1289-1292.
28. Pinotti M., Rizzotto L., Balestra D., Lewandowska M.A., Cavallari N., Marchetti G., Bernardi F., Pagani F. U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency. Blood 2008, 111:2681-2684.
29. Purcell D.F.J., Martin M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 1993, 67:6365-6378.
30. Query C.C., Bentley R.C., Keene J.D. A common RNA recognition motif identified within a defined U1 RNA binding domain of the 70K U1 snRNP protein. Cell 1989, 57:89-101.
31. Robberson B.L., Cote G.J., Berget S.M. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol. Cell Biol. 1990, 10:84-94.
32. Rossi F., Forne T., Antoine E., Tazi J., Brunel C., Cathala G. Involvement of U1 small nuclear ribonucleoproteins (snRNP) in 5' splice site-U1 snRNP interaction. J. Biol. Chem. 1996, 271:23985-23991.
33. Ruijter J.M., Thygesen H.H., Schoneveld O.J., Das A.T., Berkhout B., Lamers W.H. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology 2006, 3:1-8.
34. Sajic R., Lee K., Asai K., Sakac D., Branch D.R., Upton C., Cochrane A. Use of modified U1 snRNAs to inhibit HIV-1 replication. Nucleic Acids Res. 2007, 35:247-255.
35. Scherly D., Boelens W., van Venrooij W.J., Dathan N.A., Hamm J., Mattaj I.W. Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J. 1989, 8:4163-4170.
36. Scherly D., Boelens W., Dathan N.A., Kambach C., van Venrooij W.J., Mattaj I.W. Binding specificity determinants of U1A and U2B" proteins. Mol. Biol. Rep. 1990, 14:181-182.
37. Seppen J., Rijnberg M., Cooreman M.P., Oude Elferink R.P. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J. Hepatol. 2002, 36:459-465.
38. Suzuki K., Shijuuku T., Fukamachi T., Zaunders J., Guillemin G., Cooper D., Kelleher A. Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J. RNAi Gene Silencing 2005, 1:66-78.
39. Tanner G., Glaus E., Barthelmes D., Ader M., Fleischhauer J., Pagani F., Berger W., Neidhardt J. Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA. Hum. Mutat. 2009, 30:255-263.
40. Ter Brake, O., Berkhout, B., 2008. Development of an RNAi-based gene therapy against HIV-1. In: Kurreck, J. (Ed.), Therapeutic Oligonucleotides RSC Publishing, Cambridge, pp. 296-311.
41. Ter Brake O., Konstantinova P., Ceylan M., Berkhout B. Silencing of HIV-1 with RNA interference. A multiple shRNA approach. Mol. Ther. 2006, 14:883-892.
42. Ter Brake, O., 't Hooft, K., Liu, Y.P., Centlivre, M., von Eije, K.J., erkhout, B., 2008. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. 16, 557-564.
43. Ter Brake O., Legrand N., von Eije K.J., Centlivre M., Spits H., Weijer K., Blom B., Berkhout B. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)(c)(-/-)) mouse model. Gene Ther. 2009, 16:148-153.
44. Van Opijnen T., Jeeninga R.E., Boerlijst M.C., Pollakis G.P., Zetterberg V., Salminen M., Berkhout B. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 2004, 78:3675-3683.
45. Will C.L., Luhrmann R. Protein functions in pre-mRNA splicing. Curr. Opin. Cell Biol. 1997, 9:320-328.
46. Zhou X., Vink M., Klaver B., Berkhout B., Das A.T. Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther. 2006, 13:1382-1390.